# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

FORM 4

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

| 1. Name and Addres<br>Hallal David  | s of Reporting Person | *              | 2. Issuer Name and Ticker or Trading Symbol <u>ALEXION PHARMACEUTICALS INC</u> [ ALXN ] |                         | ionship of Reporting Person(<br>all applicable)<br>Director<br>Officer (give title                 | (s) to Issuer<br>10% Owner<br>Other (specify |  |
|---|-----------------------|----------------|---|-------------------------|--|--|--|
| (Last) (First) (Middle)<br>C/O ALEXION PHARMACEUTICALS, INC<br>100 COLLEGE STREET |                       | · · · ·        | 3. Date of Earliest Transaction (Month/Day/Year)<br>02/26/2016                          | Х                       | below) CEO   |  |  |
| (Street)<br>NEW HAVEN<br>(City)   | CT<br>(State)         | 06510<br>(Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                | 6. Indivi<br>Line)<br>X | dual or Joint/Group Filing (C<br>Form filed by One Reportir<br>Form filed by More than O<br>Person | ng Person                                    |  |

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3)           | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transaction<br>Code (Instr.<br>8) |   |                       |               |                         |                                    | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|---|--|---|---|---|-----------------------|---------------|-------------------------|------------------------------------|---|---|--|
|   |  |   | Code                                    | v | Amount                | (A) or<br>(D) | Price                   | Transaction(s)<br>(Instr. 3 and 4) |   | (11301.4)   |  |
| Common Stock, par value \$.0001 per share | 02/26/2016                                 |   | Α                                       |   | 20,000 <sup>(1)</sup> | A             | \$ <mark>0</mark>       | 193,026                            | D   |   |  |
| Common Stock, par value \$.0001 per share | 02/29/2016                                 |   | S                                       |   | 2,000 <sup>(2)</sup>  | D             | \$138.91 <sup>(3)</sup> | 191,026                            | D   |   |  |
| Common Stock, par value \$.0001 per share | 02/29/2016                                 |   | S                                       |   | 14 <sup>(2)</sup>     | D             | \$141.45(4)             | 191,012                            | D   |   |  |

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | 5. Number<br>Derivative<br>Securities<br>Acquired (A<br>Disposed o<br>(D) (Instr. 3)<br>and 5) | A) or | 6. Date Exerc<br>Expiration Da<br>(Month/Day/Y | ate                | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |                                     | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|------------------------------|---|--|-------|--|--------------------|---|-------------------------------------|---|--|--|--|
|   |   |  |   | Code                         | v | (A)  | (D)   | Date<br>Exercisable                            | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of Shares |   | Reported<br>Transaction(s)<br>(Instr. 4)                                       |  |  |
| Option to<br>Purchase<br>Common<br>Stock            | \$140.16  | 02/26/2016                                 |   | А                            |   | 131,000 <sup>(5)</sup>   |       | 02/26/2017                                     | 02/26/2026         | Common<br>Stock,<br>par value<br>\$.0001<br>per share   | 131,000                             | \$140.16  | 131,000  | D  |  |

Explanation of Responses:

1. Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date.

2. This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.

3. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$138.00 - \$138.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

4. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$141.00 - \$141.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

5. 25% vests on the first anniversary of the grant date and 1/16 every three months thereafter.

#### Remarks:

<u>/s/ Michael Greco, Attorney-in-</u> Fact for David Hallal

03/01/2016

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.